CLINICAL TRIALS PROFILE FOR TENIPOSIDE

All Clinical Trials for Teniposide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002531 ↗	Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia	Unknown status	Johann Wolfgang Goethe University Hospital	Phase 2	1993-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.
NCT00002802 ↗	Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma	Completed	Children's Hospital Medical Center, Cincinnati	Phase 3	1990-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is most effective in treating patients with different stages of and risk factors for neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of therapy based on stage of disease and risk assessment in treating children with neuroblastoma.
NCT00004231 ↗	Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1999-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation and/or biological therapy in treating patients who have stage III, stage IV, or recurrent mantle cell lymphoma.
NCT00004231 ↗	Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma	Completed	Northwestern University	Phase 2	1999-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation and/or biological therapy in treating patients who have stage III, stage IV, or recurrent mantle cell lymphoma.
NCT00004916 ↗	Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1999-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of ifosfamide, teniposide, and paclitaxel in treating patients who have relapsed non-Hodgkin's lymphoma.

Clinical Trial Conditions for Teniposide

Condition Name

Condition Name for Teniposide
Intervention	Trials
Acute Lymphoblastic Leukemia	2
Leukemia	2
Lymphoma	2
Neuroblastoma	1

Condition MeSH

Condition MeSH for Teniposide
Intervention	Trials
Leukemia	5
Leukemia, Lymphoid	4
Lymphoma	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	4

Clinical Trial Locations for Teniposide

Trials by Country

Trials by Country for Teniposide
Location	Trials
United States	7
Germany	3
China	2
Spain	1

Trials by US State

Trials by US State for Teniposide
Location	Trials
Tennessee	2
California	2
Illinois	2
Texas	1

Clinical Trial Progress for Teniposide

Clinical Trial Phase

Clinical Trial Phase for Teniposide
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Teniposide
Clinical Trial Phase	Trials
Completed	6
Unknown status	3
Recruiting	1

Clinical Trial Sponsors for Teniposide

Sponsor Name

Sponsor Name for Teniposide
Sponsor	Trials
Northwestern University	2
St. Jude Children's Research Hospital	2
National Cancer Institute (NCI)	2

Sponsor Type

Sponsor Type for Teniposide
Sponsor	Trials
Other	13
NIH	2

Teniposide: Clinical Trials Update, Market Analysis, and Projections

Introduction

Teniposide, also known as VM-26, is a chemotherapeutic agent that has been utilized in various cancer treatments, particularly in childhood acute lymphocytic leukemia (ALL) and, more recently, in the treatment of high-grade gliomas. This article provides an update on the clinical trials, market analysis, and projections for teniposide.

Clinical Trials Update

Treatment of High-Grade Gliomas

A recent case series has explored the safety and efficacy of superselective intra-arterial (IA) cerebral infusion of teniposide for patients with high-grade gliomas. In this study, 12 patients who had previously undergone standard therapy received at least two cycles of teniposide infusion after blood-brain barrier disruption. The results showed no significant adverse events, and the overall response rate and disease control rate were 50.0% and 83.3%, respectively. Two patients achieved a complete response, four had a partial response, four had stable disease, and two showed progressive disease[1].

Treatment of Refractory Cancers

In a phase I study, teniposide was administered orally for 20 consecutive days to patients with refractory cancers. The maximum tolerated dose was found to be 100 mg/day, with myelosuppression being the dose-limiting toxicity. Despite this, blood counts recovered sufficiently by day 35 to begin another 20-day course. Gastrointestinal toxicity and total alopecia were also observed in some patients[3].

Childhood Acute Lymphocytic Leukemia (ALL)

Teniposide has been established as an effective agent in combination chemotherapy for childhood ALL. It has shown consistent ability to reduce leukemic cell populations not responsive to other agents. Incorporating teniposide into combination chemotherapy has led to higher cure rates and extended remission lengths for patients, especially those at high risk of treatment failure[4].

Market Analysis

Global Market Size and Forecast

The global market for teniposide was valued at several million USD in 2023 and is forecasted to grow at a significant compound annual growth rate (CAGR) from 2024 to 2030. The market is segmented by region, with North America, Europe, and the Asia-Pacific region being key markets. The Asia-Pacific market, in particular, is expected to see substantial growth during the forecast period[2].

Market Segmentation

The teniposide market is segmented by type (purity levels of 97%, 98%, and 99%) and by application (medicine, chemical, and others). The medicine segment dominates the market due to the drug's primary use in cancer treatment. Key companies in the market include AbMole BioScience, AdooQ BioScience, Ambeed, ApexBio Technology, and others[2].

Competitive Landscape

The global teniposide market is competitive, with several key players holding a significant share of the revenue. In 2023, the top five players accounted for a substantial percentage of the market revenue. The competitive landscape is characterized by ongoing research and development, mergers, and strategic partnerships to enhance market share and product offerings[2].

Market Projections

Regional Growth

The North American, European, and Asia-Pacific markets are expected to drive the growth of the teniposide market. The Asia-Pacific region, with its large population and increasing healthcare expenditure, is anticipated to be a major contributor to the market's growth. The market in South America and the Middle East and Africa is also expected to expand, albeit at a slower pace[2].

Sales and Revenue Forecast

The global teniposide sales volume and revenue are projected to increase significantly from 2024 to 2030. The sales volume is expected to grow in terms of tons, while the revenue is forecasted in millions of USD. The average price per ton is also expected to stabilize or increase slightly during this period[2].

Challenges and Future Directions

Limitations of Current Studies

While the clinical trials for teniposide in high-grade gliomas show promising results, they are limited by small sample sizes. Future studies with larger samples and multicenter designs are necessary to confirm these findings and to assess the long-term efficacy and safety of this treatment approach[1].

Toxicity and Side Effects

Teniposide is associated with significant side effects, including myelosuppression, gastrointestinal toxicity, and alopecia. Managing these side effects while maintaining therapeutic efficacy is a critical challenge in the clinical use of teniposide[3].

Key Takeaways

• Clinical Efficacy: Teniposide has shown promise in treating high-grade gliomas and childhood ALL, with favorable response rates and disease control rates.
• Market Growth: The global teniposide market is expected to grow significantly from 2024 to 2030, driven by increasing demand in the medicine segment.
• Regional Expansion: The Asia-Pacific region is anticipated to be a major driver of market growth.
• Challenges: Small sample sizes in current studies and significant side effects are key challenges that need to be addressed.

FAQs

What is teniposide used for?

Teniposide is primarily used in the treatment of childhood acute lymphocytic leukemia (ALL) and has also been explored for the treatment of high-grade gliomas.

What are the side effects of teniposide?

Common side effects include myelosuppression, gastrointestinal toxicity, and total alopecia.

How is teniposide administered for high-grade gliomas?

Teniposide can be administered via superselective intra-arterial cerebral infusion after blood-brain barrier disruption.

What is the market forecast for teniposide?

The global teniposide market is expected to grow at a significant CAGR from 2024 to 2030, driven by increasing demand in the medicine segment.

Which regions are expected to drive the growth of the teniposide market?

The North American, European, and Asia-Pacific regions are expected to be key drivers of market growth.

Sources

1. Safety and feasibility of intra-arterial delivery of teniposide to high-grade gliomas. Journal of NeuroInterventional Surgery, 16(11), 1152.
2. Teniposide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030. QY Research.
3. A phase I study of daily oral teniposide for 20 days. PubMed.
4. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia. PubMed.